Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
muscular dystrophy
Biotech
Epicrispr bags $90M to rewrite treatment of rare muscle disease
The round positions the biotech to advance a pipeline of epigenetic medicines led by an early-phase facioscapulohumeral muscular dystrophy prospect.
Nick Paul Taylor
Aug 11, 2026 10:30am
Epicrispr gene silencer enhances muscle in muscular dystrophy
Jun 26, 2026 10:40am
Novartis dystrophy data tee up regulatory talks on Avidity drug
Jun 12, 2026 4:30am
Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit
Jun 1, 2026 8:31am
BridgeBio's muscle weakness data impress ahead of FDA filing
Mar 12, 2026 10:30am
PepGen hit with partial hold, analyst blames 'understaffed FDA'
Mar 5, 2026 5:45am
